Gilead Sciences (GILD): The Fortress Nobody's Paying Attention To

GNG Research | February 24, 2026 Healthcare Barbell Series, Part 1 of 3 Rating: BUY (Starter) | Accumulate on Weakness Current holders: HOLD, add on pullbacks to defined zones. Most investors look at Gilead Sciences (GILD) and see the same story they've seen for a decade: an HIV company treading water. They're wrong, and the mistake is costing them real money. Under the hood, Gilead is quietly assembling one of biopharma's most interesting portfolio structures, a fortress HIV franchise generating predictable cash on one end and a credible oncology and cell therapy platform on the other. Think of it like a well-built bridge: the massive concrete pylons (HIV) aren't exciting to photograph, but they're what lets the elegant suspension cables (oncology optionality) reach for the sky. At roughly $152 per share, Gilead trades near fair value on its base business alone, which means you're getting the oncology optionality nearly free. That's the setup that got us to initiate a position. This is also why GILD anchors the first leg of our three-part Healthcare Barbell, a systematic allocation designed to capture different risk and return profiles across the sector. Where Gilead provides the defensive base, TransMedics (TMDX) will bring growth-stage disruption in medical devices and Regeneron (REGN) delivers biotech pipeline optionality. Each piece solves a different portfolio problem. But the barbell only works if the anchor holds, so let's stress-test whether GILD deserves that role. The HIV Pylon: $14.3 Billion of Concrete Start with what's actually knowable. Gilead (GILD) reported full-year 2025 revenues of $29.4 billion, with Q4 revenues of $7.9 billion, up 5% year over year. Biktarvy, the crown jewel of the HIV portfolio, delivered $14.3 billion in sales, growing 7% annually in a market most investors assume is ex-growth. The broader HIV franchise grew 6% year over year, reaffirming that Gilead still owns one of the most durable revenue streams in large-cap pharma. But the real pivot isn't in daily pills. It's in the transition to long-acting formats. Yeztugo (lenacapavir), approved by the FDA in June 2025, is the first and only twice-yearly HIV prevention option. This is a big deal. Instead of asking people to remember a daily pill, you're offering protection with two injections per year. The Phase 3 PURPOSE trials showed remarkable efficacy, with more than 99.9% of participants remaining HIV-negative. This isn't an incremental improvement; it's a category shift that expands Gilead's addressable market from people already diagnosed to people at risk, a population measured in millions. One critical clarification: Sunlenca (also lenacapavir) is approved as a twice-yearly treatment for adults with multidrug-resistant HIV. It does not cure HIV. Gilead's own materials explicitly state this. The treatment indication serves a smaller, heavily treatment-experienced population, while Yeztugo's prevention indication is the much larger commercial opportunity. Management guided for approximately $800 million in combined lenacapavir revenue for 2026 (encompassing both Sunlenca treatment and Yeztugo PrEP), up from $150 million in 2025. The growth is primarily driven by Yeztugo's PrEP ramp, and Mizuho analysts have described the $800 million target as "probably conservative." But the commercial ramp won't be automatic. Coverage, pricing, guideline adoption, and channel access are the gating factors. The best drug doesn't always win fastest; it's a systems problem as much as a science problem. This is exactly the dynamic that makes (GILD) the right anchor for a healthcare barbell. The HIV franchise throws off enough cash to fund the growth bets without forcing you to bet the portfolio on any single pipeline outcome. That's the luxury you don't get with a pure biotech like REGN (our Part 3), where the upside is bigger but so is the downside if clinical data disappoints. The Oncology Suspension Cables Gilead's oncology story